265. Lipodystrophy
109 clinical trials,   164 drugs   (DrugBank: 59 drugs),   26 drug target genes,   94 drug target pathways

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00865007
(ClinicalTrials.gov)
December 200818/3/2009Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With LipoatrophyA Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/RitonavirHIV Infection;Lipodystrophy;HIV InfectionsDrug: Monotherapy (Lopinavir/ritonavir);Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TCFundacion SEIMC-GESIDAAbbottCompleted18 YearsN/ABoth88Phase 4Spain
2NCT00426296
(ClinicalTrials.gov)
August 200623/1/2007SHARE: Simple HAART With Abacavir, Reyataz, and EpivirAn Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 WeeksHIV Infections;LipodystrophyDrug: atazanavir (Reyataz);Drug: ritonavir (Norvir)Clinical Alliance for Research & Education - Infectious Diseases, LLC.GlaxoSmithKlineRecruiting18 YearsN/ABothPhase 4United States
3NCT00647946
(ClinicalTrials.gov)
February 200327/3/2008Study to Evaluate Changes in Limb Fat When Switching From a Thymidine AnalogueA Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART)LipodystrophyDrug: tenofovir DF;Drug: abacavir 300mg twice dailyGilead SciencesNULLCompleted18 YearsN/ABoth100Phase 2United Kingdom
4NCT00192660
(ClinicalTrials.gov)
February 200312/9/2005HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First TimeHIV-Associated Lipodystrophy Syndrome;Cardiovascular DiseaseDrug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/ABoth80Phase 4Australia
5NCT00028314
(ClinicalTrials.gov)
March 200220/12/2001Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV PatientsA Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat WastingHIV Infections;Lipodystrophy;Wasting DiseaseDrug: Abacavir sulfate;Drug: Atazanavir/Ritonavir;Drug: Lopinavir/Ritonavir;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth150N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00021463
(ClinicalTrials.gov)
April 200114/7/2001Changing to Nonprotease Inhibitor Treatment to Improve Side EffectsPhase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic AbnormalitiesHIV Infections;LipodystrophyDrug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth342Phase 2United States
7NCT00005764
(ClinicalTrials.gov)
May 200030/5/2000A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive PatientsGlaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)HIV Infections;LipodystrophyDrug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: LamivudineGlaxo WellcomeNULLCompleted18 YearsN/ABoth100Phase 4United States